Monetization of legacy asset brings in $3 million in nondilutive capital
Convertible notes exchange brings in another $2.8 million in new capital and reduces Biora's net debt
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with institutional investor Context Capital to invest $2.8 million in new capital alongside a convertible note exchange, and announced the monetization of its investment in privately held Enumera Molecular, Inc. ("Enumera") in a separate transaction that results in $3 million of nondilutive funding for Biora.
"Since September 2023, we have reduced Biora's debt by more than $80 million in three separate note exchange transactions with institutional investors, who also invested $19.8 million of new capital, a strong indication of investors' continued confidence in our programs. By monetizing our interest in Enumera, which is related to our legacy business, we are also bringing in additional funding to complement our shareholders' capital investment," said Eric d'Esparbes, Chief Financial Officer of Biora Therapeutics. "We continue to make substantive progress toward optimizing the capital structure of Biora, and developing our therapeutics programs, which are progressing well. We look forward to sharing data from the SAD portion of our phase 1 clinical trial during our corporate update later this month," continued Mr. d'Esparbes.
Biora has agreed with Context Capital to exchange an aggregate of $5.6 million principal amounts of its senior convertible notes due 2025 for an aggregate of $3.8 million convertible senior secured notes due 2028 issued pursuant to an indenture dated December 19, 2023 (the "2028 Notes"). Context Capital has also agreed to purchase $2.8 million of 2028 Notes and common stock ...